Background. New oral anticoagulants (NOAC; rivaroxaban, dabigatran, apixaban) have
become available as an alternative to warfarin anticoagulation in non-valvular atrial …

Background: Oral anticoagulation reduces the risk of mortality in atrial fibrillation (AF), but
examination of the causes of death is essential to design new strategies to further reduce the …

Abstract Background Direct oral anticoagulants (DOACs) have shown a positive benefit-risk
balance in both clinical trials and real-world data, but approximately 2% to 3.5% of patients …

The history of the traditional anticoagulants is marked by both perseverance and serendipity.
The anticoagulant effect of heparin was discovered by McLean in 1915, while he was …

Abstract The product Teysuno™(S‐1) contains tegafur, a prodrug of 5‐fluorouracil (5‐FU),
and two modulators of 5‐FU metabolism, gimeracil and oteracil. The main clinical study in …

Aims To analyse clinical outcomes with direct oral anticoagulants in patients with atrial
fibrillation according to geographic region. Methods We systematically searched MEDLINE …

Background Adverse cardiac remodeling is a major risk factor for the development of post
myocardial infarction (MI) heart failure (HF). This study investigates the effects of the …

Death is more frequent than nonfatal recurrent venous thromboembolism (VTE) and major
bleeding after acute VTE. The analysis of the causes of death is fundamental to explore new …

Controlled trials provide the most valid determination of the efficacy and safety of an
intervention, but large cardiovascular clinical trials have become extremely costly and …

Coinciding in time with the expiration of the patent of enoxaparin and clopidogrel, a number
of new antithrombotics (anticoagulants and antiplatelets with new mechanisms of action) …